Ablation Technology Market Forecasts to 2030 – Global Analysis By Product (Cryoablation Devices, Electrical Ablators, Hydrothermal/Hydromechanical Ablators, Laser/Light Ablators, Microwave Ablators, Radiofrequency Ablators, Ultrasound Ablators and Other P

Ablation Technology Market Forecasts to 2030 – Global Analysis By Product (Cryoablation Devices, Electrical Ablators, Hydrothermal/Hydromechanical Ablators, Laser/Light Ablators, Microwave Ablators, Radiofrequency Ablators, Ultrasound Ablators and Other Products), Technology (Thermal ablation technology, Non-thermal ablation technology and Other Technologies), Application, End User and By GeographyAccording to Stratistics MRC, the Global Ablation Technology Market is accounted for $8.49 billion in 2023 and is expected to reach $20.85 billion by 2030 growing at a CAGR of 13.7% during the forecast period. Ablation usually refers to the surgical removal of a portion of biological tissue. The procedure's devices offer a less intrusive option to traditional surgical treatment for liver, kidney, prostate, and lung cancer. It takes less time to recover because it is a minimally invasive technique and less painful than traditional surgical procedures.

According to an article by RadiologyInfo.org updated in February 2021, radiofrequency ablation (RFA), a minimally invasive treatment for cancer, employs an image-guided technique to apply heat to destroy cancer cells.

Market Dynamics:

Driver:

Hospitals will become a prominent end-user with better patient care

Hospital settings have a significantly higher incidence rate of ablation operations because these facilities guarantee the availability of trained medical professionals and cutting-edge equipment, which reduces the complexity of the procedure. Additionally, market growth will also be aided by the introduction of novel products in the ablation sector and increased government funding for enhancing hospital infrastructure.

Restraint:

High product costs inhibit growth

Depending on the patient's age and severity, the cost of the treatment varies. Catheter ablation will cost approximately 1–1.25 lakh rupees in India. The cost may vary according to the hospital, the surgeon, etc. Eckard et al. estimated the cost of ablation in a decision-analytic model to be about USD 58,000 per quality-adjusted life year. This cost is forecast without assuming that the ablation approach will prevent strokes. Therefore, the worldwide ablation technology market's expansion may be constrained by its expensive price.

Opportunity:

Growing demand for non-invasive and minimally-invasive techniques

Due to the benefits that these procedures offer over conventional treatment methods fewer operative complications, fewer hospital stays, less pain, smaller and more aesthetic incisions, lower risk of infection, reduced post-operative care, and a faster recovery—the demand for minimally invasive procedures has increased significantly. Modern technology is used in minimally invasive procedures to identify and treat diseases like cancer. These techniques are used to remove lymph nodes and cancerous tumors without leaving wounds. Surgeons can also collect samples for biopsies and precise staging tests with the help of minimally invasive procedures.

Threat:

Reusing and processing old technology

Ablation catheters are classified as single-use devices (SUDs) under FDA and EU regulations. Hospitals with limited funds, however, are switching to reprocessing and reuse because of the high per-unit cost and low reimbursement. In comparison to the price of a new ablation device, the cost incurred by a hospital or surgical center for reprocessing and reuse is less than 10%, cutting the whole procedure cost by about 50%. Under the condition that the devices are recycled in accordance with regulatory criteria, Germany is one of the major European nations that permits the reuse of SUDs (including ablation catheters).

Covid-19 Impact:

The COVID-19 epidemic posed significant hurdles for the healthcare sector. Since the majority of chronic therapy was considered non-urgent, all outpatient treatments were delayed or restricted during the COVID-19 pandemic in order to lower the danger of viral transmission. For instance, according to a report published in November 2022 in PubMed, catheter ablation (CA) drastically collapsed in the early stages of the COVID-19 pandemic before gradually recovering to pre-COVID-19 levels. The number of ablation surgeries accomplished during the period is significantly less than that of the prior year due to the COVID-19 pandemic's suspension of all non-urgent elective surgical procedures.

The cancer treatment segment is expected to be the largest during the forecast period

Due to the increasing number of cancer patients worldwide, the Cancer Treatment segment held the largest market share over the projection period. For small tumors, radiofrequency treatment is one of the most popular ablation techniques. Without the need for traditional surgery, special probes are utilized to ""burn"" or ""freeze"" tumors. Additionally, the needle probe is guided and positioned into the tumor using magnetic resonance imaging (MRI), ultrasound, or computed tomography (CT). For instance, the IARC predicts that there will be 28.9 million new instances of cancer worldwide by 2040.

The radiofrequency ablators segment is expected to have the highest CAGR during the forecast period

Owing to the increasing use of cutting-edge Radio Frequency (RF) technologies in healthcare as well as the introduction of new products into the market by major market players, the radiofrequency ablators segment is predicted to grow profitably throughout the dominance period. This is driving up demand for radiofrequency ablators. Additionally, when used in combination with a suitable multi-channel RF generator, it is permitted for cardiac ablation and catheter-based cardiac electrophysiology mapping of the atria.

Region with largest share:

Due to improved Research and Development (R&D) for the design of effective ablation products and increasing adoption of new technologies, North America is predicted to hold the largest market share throughout the extrapolated period. Furthermore, the use of more advanced methods and systems in the production of ablation devices, as well as technological developments in ablation device research, are anticipated to drive the market's expansion in the North American region.

Region with highest CAGR:

Due to the increasing prevalence and incidence of cancer and cardiac conditions, technological advancements in ablation products and technology, growing awareness of minimally invasive techniques, and growth opportunities in emerging markets, the Asia-Pacific region commanded lucrative growth during the estimated period. Moreover, the enormous populations affected by chronic diseases and the growing need for ablation devices for rapid identification and treatment of these diseases are also anticipated to fuel the ablation device market's expansion in the region.

Key players in the market

Some of the key players in Ablation Technology market include Johnson & Johnson, Smith & Nephew PLC, Abbott Laboratories, Smith & Nephew plc, Boston Scientific, Olympus Corporation, Medtronic, Varian Medical Systems, AngioDynamics, Inc, Dornier MedTech, AtriCure, Inc. and Alcon Laboratories.

Key Developments:

In October 2022, The C2 CryoBalloon Ablation System was released in Canada to treat Barrett's Esophagus. This was done by PENTAX Medical, a company in the healthcare industry that makes diagnostic and therapeutic endoscopy solutions.

In March 2022, Quantum Surgical received 510(k) clearance from the United States Food and Drug Administration for the Epione robot, which can plan, target, deliver, and confirm tumor ablation for cancer treatment.

In January 2022, Medtronic plc entered into a definitive agreement to acquire Affera, Inc. The acquisition expands the Medtronic portfolio of advanced cardiac ablation products and accessories to meet physician needs within a growing patient population.

In January 2022, Affera, a provider of medical technology, reached a formal agreement under which Medtronic will acquire the company for USD 925 million. Through its portfolio of minority investments, Medtronic has been a strategic investor in Affera and now has a 3% stake in the company.

Products Covered:
• Cryoablation Devices
• Electrical Ablators
• Hydrothermal/Hydromechanical Ablators
• Laser/Light Ablators
• Microwave Ablators
• Radiofrequency Ablators
• Ultrasound Ablators
• Other Products

Technologies Covered:
• Thermal ablation technology
• Non-thermal ablation technology
• Other Technologies

Applications Covered:
• Cardiovascular Disease Treatment
• Cancer Treatment
• Gynecological Treatment
• Cosmetic/ Aesthetic Surgery
• Pain Management
• Orthopedic Treatment
• Urological Treatment
• Ophthalmologic Treatment
• Other Applications

End Users Covered:
• Ambulatory Surgical Centers
• Hospitals and ablation centers
• Medical Spas & Aesthetic clinics
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements